Walkner Condon Financial Advisors LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Walkner Condon Financial Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 797 shares of the company’s stock after buying an additional 61 shares during the quarter. Walkner Condon Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $720,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in LLY. Norges Bank bought a new stake in Eli Lilly and Company during the 4th quarter valued at $5,992,890,000. Swedbank AB bought a new stake in Eli Lilly and Company during the first quarter valued at about $932,797,000. Sapient Capital LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $682,139,000. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after purchasing an additional 1,133,810 shares in the last quarter. Finally, GQG Partners LLC lifted its position in shares of Eli Lilly and Company by 20.2% during the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after buying an additional 648,094 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Argus boosted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Guggenheim upped their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $961.76.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,120,089 shares of company stock valued at $990,278,343 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $5.54 during trading on Wednesday, hitting $948.94. 1,679,095 shares of the company’s stock were exchanged, compared to its average volume of 3,081,237. The stock has a market capitalization of $901.88 billion, a price-to-earnings ratio of 140.80, a PEG ratio of 1.81 and a beta of 0.41. The business has a 50-day simple moving average of $887.63 and a 200-day simple moving average of $816.72. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.